EPISODE · May 12, 2025 · 8 MIN
#013 $NVO: The Weight-Loss Hype That Shrank Portfolios
from Bulls & Betrayal · host bullsandbetrayal
Novo Nordisk (NVO) made waves with promises of 25% weight loss from its new drug CagriSema—but when final trial results dropped below expectations, investors were blindsided. In this episode of Bulls & Betrayal: Holding Wall Street Accountable, Anna and Nate dig into the REDEFINE-1 study, “flexible protocols,” and the class action lawsuit that followed. If you're an investor, financial sleuth, or anyone tracking pharma giants and stock fraud, this one’s for you. Expect deep dives, candid takes, and no sugar-coating. 💼 We’re not lawyers or accountants, so don’t take this as legal or financial advice. 👀 Learn more at ZLK.com
Embed this episode
NOW PLAYING
#013 $NVO: The Weight-Loss Hype That Shrank Portfolios
No transcript for this episode yet
Similar Episodes
No similar episodes found.